U.S. flag An official website of the United States government

U.S. Food and Drug Administration
  1. Home
  2. Drug Databases
  3. REMS

Approved Risk Evaluation and Mitigation Strategies (REMS)

Xiaflex (collagenase clostridium histolyticum)
BLA #125338
REMS last update: 11/02/2022



What is the purpose of the REMS?

    1. The goal of the XIAFLEX REMS is to mitigate the risks of corporal rupture (penile fracture) and other serious penile injuries associated with the use of XIAFLEX for Peyronie’s disease by:
      1. Training healthcare providers in how to properly administer XIAFLEX.
      2. Informing healthcare providers about the risks of corporal rupture (penile fracture)and other serious injuries to the penis.
      3. Informing healthcare providers about the need to counsel patients to communicate that risks of corporal rupture and other serious penile injuries are associated with the use of XIAFLEX in treating Peyronie’s disease and that patient adherence to post-injection instructions is important for the drug’s safety and effectiveness.
      4. Ensuring that XIAFLEX is dispensed only in certified pharmacies or healthcare settings for the treatment of Peyronie’s disease.
      5. Informing patients about the risks of corporal rupture and other serious penile injuries associated with the use of XIAFLEX in treating Peyronie’s disease and that adherence to post-injection instructions is important for the drug’s safety and effectiveness.

What do participants need to know?

Below is a general overview of the REMS for all REMS participants (e.g., patients, pharmacies, and healthcare providers). See the application holder(s) REMS Website or the approved REMS materials for more information.

View application holder(s) REMS Website See Disclaimer page regarding links to external sites

What assessment is available to the REMS?

Assessment Plan
REMS assessment plan unavailable for posting at this time.

What updates have been made to the REMS?

Date Summary of change
11/02/2022 Modified to:

  1. Convert the REMS Document to the new, standardized format
  2. Make changes to the Patient Counseling Tool based on the results from qualitative testing studies
  3. Improve website functionality due to a change in REMS administrator
06/09/2022 Modified to remove the mail-in option for healthcare provider and pharmacy/healthcare setting enrollment and other minor updates due to a REMS administrator change.
01/11/2022 Modified to update the REMS materials to reflect the safety labeling changes that were recently approved on August 19, 2021 and approved labeling regarding penile hematoma.
10/30/2018 Revised to reflect minor editorial changes.
09/26/2018 Modified to revise REMS educational materials to align with safety labeling changes.
07/10/2018 Revised to reflect a change in ownership.
01/25/2017 Revised to correct a typographical error (s).
11/28/2016

  1. Modified the REMS for the treatment of Dupuytren’s contracture to:
    1. Remove the communication plan from the REMS.
    2. Release the REMS requirements.
  2. Modified the REMS for the treatment of Peyronie’s disease to:
    1. Change to the Prescriber Material, “Training Guide for the Administration of Xiaflex for Peyronie’s Disease”
    2. Change to the Patient Counseling Tool, “What You Need to Know About XIAFLEX Treatment for Peyronie’s Disease: A Patient Guide”
    3. Align the Training Video with the Prescriber Material.
    4. Align the Xiaflex REMS Program website with the Prescriber Material.
    5. Remove information related to the communication plan.
10/20/2014

  1. Modified the REMS for the treatment of Dupuytren’s contracture to:
  1. Include the following change to information in the dosing regimen: two concurrent injections of Xiaflex into palpable cords affecting multiple joints in the same hand in adult patients with Dupuytren’s contracture with finger extension procedure 24 to 72 hours after injection; and
  2. Include the risk of skin laceration requiring skin graft in patients treated with Xiaflex (collagenase clostridium histolyticum) in the communication plan materials (Dear Healthcare Provider Letter; Training Guide for the Administration of Xiaflex; and Xiaflex Procedure Training Video).
12/06/2013 Modified to ensure that the benefits of the drug outweigh the risk of corporal fracture (penile fracture) and other serious penile injuries by ensuring that healthcare providers who prescribe XIAFLEX (collagenase clostridium histolyticum) for Peyronie’s disease are specially certified, and that pharmacies or healthcare settings that dispense XIAFLEX (collagenase clostridium histolyticum) for Peyronie’s disease are specially certified.
02/24/2012 Modified to:

  1. Eliminate the requirement for the Medication Guide as an element of the REMS.
  2. Address the requirements in our June 1, 2011 REMS Modification Notification letter to revise some of the communication plan materials to more effectively educate prescribers about the risks when injecting Xiaflex into a cord of the proximal interphalangeal joint of the fifth finger.
02/02/2010 Approval of the REMS.

Disclaimer: This webpage provides general information about REMS programs to various REMS participants (e.g., patients, pharmacies, and healthcare providers). The summary information provided herein is not comprehensive and may not include all of the information relevant to REMS participants. This webpage does not constitute a replacement, modification, or revision of the approved REMS document, including any appended REMS materials. Refer to the approved REMS document for complete information on the REMS requirements for each approved application.

Back to Top